Monoclonal antibody manufacturing in transgenic plants — myths and realities
✍ Scribed by Elizabeth E Hood; Susan L Woodard; Michael E Horn
- Publisher
- Elsevier Science
- Year
- 2002
- Tongue
- English
- Weight
- 67 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0958-1669
No coin nor oath required. For personal study only.
✦ Synopsis
The number and types of antibodies expressed in plants has increased steadily since the first reports of this accomplishment in the 1980s, illustrating the versatility of plants as a production system for antibodies. Many recent reviews have detailed the antibody forms that have been derived from plant expression systems. This contribution focuses on the remaining challenges to develop plant-derived therapeutic antibodies into products, and some of the progress that is being made in addressing these challenges.
📜 SIMILAR VOLUMES
Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for therapeutic purposes. The isolation and engineering of the corresponding genes is becoming less of a bottleneck in the process; however, the production of recombinant antibodies is itself a limiting factor and
The increasing use of monoclonal antibodies (mAbs) in diagnostic reagents necessitates efficient and cost-effective mAb production methods. In blood banks, one of the most routinely used reagents is the antihuman IgG reagent used for the detection of nonagglutinating antibodies. Here we report the p